SCHEMBL7686239

SCHEMBL7686239

Oc1cccc2[nH]c(COc3cc(Cl)cc(Cl)c3)nc12

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRIN1 Q05586 1/20 0.49
GRIN2B Q13224 1/20 0.49
RAB9A P51151 7/20 0.48
NPC1 O15118 6/20 0.48
SMN1; SMN2 Q16637 5/20 0.48
POLB P06746 1/20 0.48
TDP1 Q9NUW8 1/20 0.48
PDE10A Q9Y233 1/20 0.45
TP53 P04637 3/20 0.43
TSHR P16473 1/20 0.43
ALDH1A1 P00352 1/20 0.42
KMT2A Q03164 2/20 0.42
MEN1 O00255 1/20 0.42
LMNA P02545 1/20 0.42
GAA P10253 1/20 0.42
MAPK1 P28482 1/20 0.42
HTT P42858 1/20 0.42
PIM1 P11309 1/20 0.42
PIM2 Q9P1W9 1/20 0.42
COASY Q13057 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7689730 0.91 RAB9A (0.51) GRIN1GRIN2BRAB9ANPC1SMN1; SMN2
SCHEMBL7687482 0.88 RAB9A (0.63) GRIN1GRIN2BRAB9ANPC1SMN1; SMN2
SCHEMBL7963333 0.84 RAB9A (0.48) RAB9ANPC1SMN1; SMN2POLBTDP1
SCHEMBL7684643 0.80 NPC1 (0.63) GRIN1GRIN2BRAB9ANPC1SMN1; SMN2
SCHEMBL7686234 0.79 RAB9A (0.48) RAB9ANPC1SMN1; SMN2POLBTDP1
SCHEMBL7688380 0.78 RAB9A (0.76) RAB9ANPC1SMN1; SMN2POLBTDP1
SCHEMBL7691472 0.75 GAA (0.53) RAB9ANPC1SMN1; SMN2POLBTDP1
SCHEMBL4066021 0.74 GRIN1 (0.54) GRIN1GRIN2BRAB9APDE10ATSHR
SCHEMBL7689804 0.72 RAB9A (0.63) RAB9ANPC1SMN1; SMN2POLBTDP1
SCHEMBL9533100 0.72 GRIN1 (0.55) GRIN1GRIN2BRAB9ATDP1PDE10A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20020007071-A1 Benzimidzolyl neuropeptide Y receptor antagonists BRITTON THOMAS CHARLES (US) 2002-01-17 US disclosed
US-6255494-B1 SUBSTITUTED BENZIMIDAZOLES USEFUL IN TREATING OR PREVENTING CONDITIONS ASSOCIATED WITH EXCESS OF NEUROPEPTIDE Y (AROUND ARTERIES IN HEART, RESPIRATORY TRACT, GASTROINTESTINAL TRACT AND GENITOURINARY TRACT); ETIOLOGY OF PSYCHIATRIC DISORDERS ELI LILLY AND COMPANY 2001-07-03 US disclosed
EP-0871442-A1 BENZIMIDZOLYL NEUROPEPTIDE Y RECEPTOR ANTAGONISTS ELI LILLY AND COMPANY (US) 1998-10-21 EP disclosed
WO-1997025041-A1 BENZIMIDZOLYL NEUROPEPTIDE Y RECEPTOR ANTAGONISTS ELI LILLY AND COMPANY (US) 1997-07-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020007071-A1 Benzimidzolyl neuropeptide Y receptor antagonists NPY1R, NPY2R, NPY5R GRIN1 804/4885GRIN2B 722/4885RAB9A 3072/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.